Escitalopram

Escitalopram is a member of the SSRI family of antidepressants ^[1][3]. Chemically it is the S-enantiomer of citalopram, meaning that where citalopram is a fifty-fifty mixture of two mirror-image forms, escitalopram contains only the more pharmacologically active form, with the inactive R-enantiomer left out ^[1][3]. It is marketed as an oxalate salt and is often described as the most selective of the SSRIs for the serotonin transporter ^[1]. Its molecular formula is C20H21FN2O ^[1].

Escitalopram was developed jointly by the Danish company Lundbeck and the American firm Forest Laboratories, building on the earlier drug citalopram ^[1]. Its development began in the late 1990s, and it was approved by the United States Food and Drug Administration for major depression in 2002, followed by approval for generalized anxiety disorder in 2003 ^[1]. It is sold under trade names including Lexapro and Cipralex, and generic versions became available later in the decade ^[1]. It appears on the World Health Organization's List of Essential Medicines ^[1].

The main approved uses of escitalopram are major depressive disorder and generalized anxiety disorder, and in Europe it is additionally licensed for social anxiety disorder, obsessive-compulsive disorder, and panic disorder ^[1]. Its efficacy has been examined in large comparative analyses; a widely cited network meta-analysis of 21 antidepressants found escitalopram to be among the more effective and better-tolerated options for the acute treatment of depression in adults ^[2]. Other systematic reviews have evaluated antidepressants, including escitalopram, for preventing relapse during longer-term maintenance treatment ^[4].

Escitalopram is a prescription-only medicine taken orally, available as tablets and an oral solution ^[1]. Commonly reported side effects include nausea, headache, sleepiness or insomnia, dry mouth, and sexual dysfunction such as difficulty with ejaculation or reduced libido ^[1]. Like other antidepressants, its labeling in many countries carries a warning about a possible increase in suicidal thoughts among children and young adults, and regulators have noted that sexual side effects may sometimes persist after the drug is stopped ^[1]. The drug can cause a mild, dose-related lengthening of the heart's QT interval, which has led some regulators to cap the maximum recommended daily dose in older adults and people with liver impairment ^[1]. Stopping the medication abruptly can produce discontinuation symptoms, so gradual tapering is generally advised ^[1].

Escitalopram is an SSRI with typical class effects: nausea and other GI upset, sexual dysfunction, sleep changes, and sweating, along with a discontinuation syndrome if stopped abruptly. Combining it with other serotonergic drugs or MAOIs can cause serotonin syndrome, it carries a dose-dependent risk of QT-interval prolongation, and it can lower blood sodium (hyponatremia), particularly in older adults. Like all antidepressants it carries a warning for increased suicidal thoughts in adolescents and young adults, so mood should be monitored, especially early in treatment.

Escitalopram is metabolized by CYP2C19, CYP2D6, and CYP3A4. When coadministered with the CYP2C19 inhibitor cimetidine, escitalopram exposure increased 72%; with omeprazole (also a CYP2C19 inhibitor), exposure increased 51% ^[6]. These pharmacokinetic changes were deemed not clinically relevant by the authors. Of greater concern is serotonin syndrome when escitalopram is used with linezolid, an antibiotic with monoamine oxidase inhibitory properties; escitalopram appears to be at particularly high risk among SSRIs for this pharmacodynamic interaction ^[7]. Escitalopram itself is a weak inhibitor of CYP450 enzymes, suggesting it rarely causes clinically significant drug interactions as the perpetrator. Interactions with drugs metabolized by CYP2D6 or CYP3A4 and with other serotonergic agents beyond linezolid remain incompletely documented.

Checking a whole stack? Run it through interactions + stacks.

Escitalopram is the purified S-enantiomer of citalopram, developed by the Danish pharmaceutical company Lundbeck in collaboration with Forest Laboratories through chiral resolution of the older racemic drug. The rationale was that nearly all of citalopram's therapeutic activity resides in the left-handed molecule, so isolating it could concentrate the benefit and simplify the pharmacology.

Escitalopram received U.S. Food and Drug Administration approval in 2002 and was marketed as Lexapro in the United States and Cipralex in many other countries, indicated for major depressive disorder and generalized anxiety disorder. It went on to become one of the most widely prescribed antidepressants in the world, prized for its clean receptor profile. Among the selective serotonin reuptake inhibitors, escitalopram is notable for having the greatest selectivity for the serotonin transporter over the transporter for norepinephrine.

Escitalopram is often described by prescribers as a benchmark SSRI, and it consistently performs well in comparative analyses of antidepressant efficacy and tolerability. Its reputation rests on a combination of reliable effect, a comparatively favorable side-effect profile, and few drug interactions, which together make it a common first-line choice for depression and anxiety. Patients frequently tolerate it well relative to older antidepressants.

Balanced against this, it shares the class-wide caveats of the SSRIs, including possible early activation or gastrointestinal upset, sexual side effects, a dose-related effect on the heart's QT interval, and the need to taper gradually to avoid discontinuation symptoms. There has also been longstanding scientific debate over how much advantage the single enantiomer truly offers over generic citalopram. On the whole, escitalopram remains one of the most trusted and extensively used antidepressants available.